Scarica l'app Stockscreener
25.99
0.76%
-0.20
Pre-mercato:
26.89
0.90
+3.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SDGR Giù?
Forum
Previsione
Precedente Chiudi:
$26.19
Aprire:
$26.74
Volume 24 ore:
1.54M
Relative Volume:
1.32
Capitalizzazione di mercato:
$1.87B
Reddito:
$193.35M
Utile/perdita netta:
$-177.58M
Rapporto P/E:
-10.61
EPS:
-2.45
Flusso di cassa netto:
$-172.43M
1 W Prestazione:
+1.54%
1M Prestazione:
+19.22%
6M Prestazione:
+39.13%
1 anno Prestazione:
+6.12%
Intervallo 1D:
$25.69
$26.89
Intervallo di 1 settimana:
$23.57
$26.89
Portata 52W:
$16.60
$28.47
Schrodinger Inc Stock (SDGR) Company Profile
Nome
Schrodinger Inc
Settore
Industria
Telefono
503-299-1150
Indirizzo
1540 BROADWAY, NEW YORK, NY
Confronta SDGR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
25.99 | 1.87B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
215.78 | 36.24B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
52.40 | 9.99B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
43.23 | 7.43B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
83.45 | 7.23B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.45 | 6.36B | 906.14M | -52.62M | 89.62M | -0.3621 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-02 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | Ripresa | Piper Sandler | Overweight |
| 2022-12-19 | Iniziato | Goldman | Neutral |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-10-13 | Iniziato | Berenberg | Buy |
| 2021-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | Iniziato | Craig Hallum | Buy |
| 2020-11-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-10-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-02 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-02 | Iniziato | Jefferies | Hold |
| 2020-03-02 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Schrodinger Inc Borsa (SDGR) Ultime notizie
Schrödinger to Announce First Quarter 2025 Financial Results on May 7 - Yahoo Finance
3 Momentum Stocks That Could Soar Post-Market Volatility - Investing.com
3 Momentum Stocks That Could Soar Post-Market Volatility - MarketBeat
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - 01net
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SDGR Stock News - GuruFocus
Schrödinger (NASDAQ:SDGR) shareholders are up 29% this past week, but still in the red over the last five years - simplywall.st
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last? - MSN
An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 26% Undervalued - Yahoo Finance
Schrodinger price target raised to $32 from $30 at KeyBanc - TipRanks
Schrodinger’s Karen Akinsanya sells $419,570 in stock By Investing.com - Investing.com South Africa
Schrodinger’s Karen Akinsanya sells $419,570 in stock - Investing.com
Schrodinger issues statement on FDA phasing out animal testing requirement - TipRanks
FDA recent move marks paradigm shift in drug development, boosting Schrödinger (SDGR) and other biotech stocks - Investorsobserver
Schrodinger (SDGR) Backs FDA's Initiative to Cut Animal Testing in Drug Development | SDGR Stock News - GuruFocus
Schrödinger's Statement Regarding FDA Plan to Phase Out Animal T - GuruFocus
Schrödinger backs FDA’s move away from animal testing By Investing.com - Investing.com South Africa
Schrodinger to Launch Predictive Toxicology Tool in H2 - marketscreener.com
Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs - 01net
Schrödinger backs FDA’s move away from animal testing - Investing.com Australia
Schrödinger'S Statement Regarding FDA Plan To Phase Out Animal Testing Requirement For Monoclonal Antibodies And Other Drugs - MarketScreener
Vanguard Group Inc. Lowers Holdings in Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade) - Seeking Alpha
Schrödinger (SDGR) Reveals Promising Preclinical Data for Cancer Inhibitors - GuruFocus
Schrodinger Settles Lawsuit Over Director Compensations; Shares Up - MarketScreener
Schrödinger (SDGR) Faces Cash Burn Challenges Amid Growth - GuruFocus
Schrodinger settles director pay lawsuit, to reform governance By Investing.com - Investing.com South Africa
Schrodinger settles director pay lawsuit, to reform governance - Investing.com
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements - Benzinga
Schrodinger Stock Hits 52-Week Low at $16.64 Amid Market Challenges - Investing.com
Schrödinger, Inc. (NASDAQ:SDGR) Shares Purchased by Massachusetts Financial Services Co. MA - MarketBeat
Top 5 AI & Digital Biotech Companies (April 2025) - Securities.io
Swiss National Bank Has $2.41 Million Stock Position in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger (NASDAQ:SDGR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Schrödinger Finally Embraces AI – Is It a Buy? - Nanalyze
Schrödinger to Present Preclinical Data at AACR Annual Meeting - 01net
Schrödinger to Present at Four Investor Conferences in September - Business Wire
(SDGR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Schrodinger Inc (SDGR) Trading Down 1.72% on Mar 21 - GuruFocus.com
Schrodinger at KeyBanc Forum: Computational Drug Discovery Focus By Investing.com - Investing.com South Africa
Schrodinger at KeyBanc Forum: Computational Drug Discovery Focus - Investing.com India
(SDGR) Proactive Strategies - Stock Traders Daily
Proficio Capital Partners LLC Purchases Shares of 11,285 Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger adds Bridget van Kralingen to board By Investing.com - Investing.com Australia
Schrodinger at Leerink Global: Strategic Growth and Challenges - Investing.com India
Schrodinger appoints Bridget van Kralingen to board By Investing.com - Investing.com Canada
Schrödinger Appoints Bridget van Kralingen To Board - citybiz
Schrodinger appoints Bridget van Kralingen to board - Investing.com
Schrödinger adds Bridget van Kralingen to board - Investing.com India
Schrodinger Inc Azioni (SDGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Schrodinger Inc Azioni (SDGR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Akinsanya Karen | President of R&D, Therapeutics |
Apr 14 '25 |
Sale |
25.09 |
16,723 |
419,570 |
15,625 |
1.29%
0.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):